All In Biotech

Drug Trial Radar · NCT03840148

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis

Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 661 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

661

Actual

Start

Aug 7, 2019

Primary completion

Dec 14, 2021

Study completion Dec 14, 2021

Sponsor

Lead sponsor
Venatorx Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.

Conditions

  • Urinary Tract Infections
  • Acute Pyelonephritis

Interventions

  • Cefepime/VNRX-5133 (taniborbactam)Drug

    Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.

  • MeropenemDrug

    Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) PopulationTime frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)

Locations

78 sites in 15 countries. Site status is shown where the registry gives one.

  • Site 184003

    Buena Park, California

  • Site 184002

    Chula Vista, California

  • Site 184001

    La Mesa, California

  • 184012

    Northridge, California

  • Site 103203

    Córdoba, Argentina

  • Site 107601

    Belo Horizonte, Brazil

  • Site 107608

    São Paulo, Brazil

  • Site 110009

    Gabrovo, Bulgaria

  • Site 110002

    Pleven, Bulgaria

  • Site 110007

    Plovdiv, Bulgaria

  • Site 110003

    Rousse, Bulgaria

  • Site 110010

    Sofia, Bulgaria

  • Site 110004

    Sofia, Bulgaria

  • Site 110005

    Sofia, Bulgaria

  • Site 110008

    Sofia, Bulgaria

  • Site 110001

    Veliko Tarnovo, Bulgaria

  • Site 156022

    Baotou, China

  • Site 156002

    Beijing, China

  • Site 156006

    Beijing, China

  • Site 156015

    Chendu, China

  • Site 156011

    Chongqing, China

  • Site 156012

    Chongqing, China

  • Site 156004

    Dalian, China

  • Site 156030

    Fujian, China

  • Site 156014

    Guangdong, China

  • Site 156027

    Guangdong, China

  • Site 156025

    Guangzhou, China

  • Site 156018

    Guiyang, China

  • Site 156003

    Nanchang, China

  • Site 156005

    Nanjing, China

  • Site 156008

    Nanjing, China

  • Site 156007

    Nanjing, China

  • Site 156013

    Ningbo, China

  • Site 156028

    Shandong, China

  • Site 156017

    Shanghai, China

  • Site 156016

    Shijiazhuang, China

  • Site 156020

    Tianjin, China

  • Site 156029

    Ürümqi, China

  • Site 156010

    Xiamen, China

  • Site 119103

    Split, Croatia

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.